![]() ![]() The biosimilar was approved in July 2020. Designed and built with patients in mind, healthcare professionals and patients don’t have to miss a beat with Hulio they simply, ‘Click, Click, Go.'" Patients remove the cap and push the device against their skin to trigger their injection. "Biocon Biologics is pleased to make Hulio, a patient-friendly, 2-click, prefilled pen available in the United States for patients with certain inflammatory diseases” said Mathew Erick, chief commercial officer of advanced markets at Biocon Biologics, in a statement. ![]() The biosimilar is available in a prefilled syringe and autoinjector pen. It does not have an interchangeability designation and the Biocon Biologics has not indicated that it will try to obtain the label. Hulio is a low-concentration adalimumab product that is citrate-free, allowing for less injection site pain during administration. Hulio and the Biocon Biologics/Viatris Portfolio Transfer It is indicated for decreasing signs and symptoms of diseases such as rheumatoid (RA), juvenile idiopathic arthritis, psoriatic arthritis (PsA), ankylosing spondylitis, Crohn disease, adult ulcerative colitis, and plaque psoriasis.Įarlier in 2023, Fresnius Kabi launched its first US biosimilar Stimufend (pegfilgrastim-fgpk), a pegfilgrastim biosimilar. The Idacio branded biosimilar is offered in over 35 countries. “Our adalimumab biosimilar forms part of a dedicated pipeline of affordable and high-quality immunology biosimilars from Fresenius Kabi, aimed to improve the quality of life of patients with chronic diseases,” according to the press release. “We are thrilled to launch Idacio, our first immunology biosimilar in the U.S.,” said Ali Ahmed, senior vice president, Biosimilars at Fresenius Kabi USA. It will be offered in a self-administered prefilled syringe and a self-administered pre-filled pen (autojector). FDA approval of Idacio was granted in December 2022, and the biosimilar will be used for 7 of the 11 indications of the reference product, Humira (adalimumab). It is a low-concentration, citrate-free product. Fresenius Kabi launched Idacio, its first immunology biosimilar. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |